AbCellera Biologics Net Income

AbCellera Biologics (ABCL) currently reports a net income of $-160M as of June 2026. That compares with $-170M in the prior-year period — up 0.6% year over year. That is below the sector sector average of $98M. Use the charts on this page to explore AbCellera Biologics's net income history and peer comparisons.

AbCellera Biologics's net income increased from $-170M to $-160M — a 0.6% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

AbCellera Biologics's net income of $-160M is lower than the its sector sector average of $98M. That is roughly 268.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

AbCellera Biologics reported $-160M in net income as of June 2026. That compares with $-170M in the prior-year period — up 0.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-160M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $98M. From there, open related valuation or income-statement pages for AbCellera Biologics, and consider following ABCL for alerts when major investors trade the stock.